Skip to main content

Drug Interactions between memantine and Tussin DM Clear

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

dextromethorphan memantine

Applies to: Tussin DM Clear (dextromethorphan / guaifenesin) and memantine

MONITOR: Coadministration of memantine with other N-methyl-D-aspartate (NMDA) antagonists such as amantadine, ketamine or dextromethorphan may result in additive CNS effects. Data are limited and the clinical significance is unknown.

MANAGEMENT: Caution and clinical monitoring are advised when memantine is coadministered with other N-methyl-D-aspartate (NMDA) antagonists. If coadministration is required, close clinical monitoring for adverse effects (e.g., sedation, psychosis) is advised and dose adjustments may be required, particularly when memantine is initiated or withdrawn from therapy. Individual product labeling should be consulted. Some authorities recommend avoiding the combination of memantine with other NMDA antagonists.

References (4)
  1. (2025) "Product Information. Memantine Hydrochloride (memantine)." Amneal Pharmaceuticals LLC
  2. (2021) "Product Information. Ebixa (memantine)." Lundbeck Ltd
  3. (2020) "Product Information. ACT Memantine (memantine)." Teva Canada Limited
  4. (2020) "Product Information. Ebixa (memantine)." Lundbeck Australia Pty Ltd

Drug and food interactions

Moderate

dextromethorphan food

Applies to: Tussin DM Clear (dextromethorphan / guaifenesin)

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References (4)
  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  4. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Nmda antagonists

Therapeutic duplication

The recommended maximum number of medicines in the 'NMDA antagonists' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'NMDA antagonists' category:

  • memantine
  • Tussin DM Clear (dextromethorphan/guaifenesin)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer